Introduction
One of the prevalent conditions brought on by a localized cardiac lesion is complete heart block (CHB), which can arise from a number of different aetiologies. Heart involvement (CI) in scleroderma patients is either related to pulmonary arterial hypertension or directly caused by myocardial fibrosis or ischemia. Scleroderma patients have been documented to develop arrhythmia-related signs and symptoms.
What Is Scleroderma?
A class of uncommon disorders called scleroderma, often called systemic sclerosis, causes the skin to become taut and rigid. Additionally, it could result in issues with the digestive system, internal organs, and blood vessels. Oftentimes, scleroderma is classified as "limited" or "diffuse," which solely relates to the extent of skin involvement. Any other vascular or organ issues may be present in either kind. Morphea, another name for localized scleroderma, is a skin-only condition. Scleroderma has no known cure, although there are therapies that can lessen symptoms, stop the disease's development, and enhance quality of life.
What Causes Scleroderma?
An excess of collagen and its buildup in bodily tissues cause scleroderma. All of the body's connective tissues, including the skin, are composed of the fibrous protein collagen.
Immunity is involved in the process. A confluence of reasons, such as autoimmune disorders, genetics, and stimuli from the surroundings, most likely brings on Scleroderma.
The likelihood of getting scleroderma seems to be influenced by many combinations of factors, including:
-
Environmental triggers.
-
Genetics.
-
Immune system problems.
What Pathogens Are Associated With Cardiac Involvement in Scleroderma?
Microvascular lesions in the heart are one of the characteristics of cardiac ischemia. Conduction block may occur more frequently in focal ischemia of the microvascular structure and functional problems. Another pathophysiologic marker of cardiac ischemia that may have an impact on the prognosis of people with scleroderma is myocardial fibrosis. Progressive fibrosis, collagen deposition, and degenerative alterations may result in the destruction of the atrioventricular node, His bundle, or left and right bundle branches. In scleroderma-related cardiac heart block instances, the proximal section of the node was narrow and about the same width as the distal part that the postmortem histological investigation had shown, rather than the typical pear-shaped proximal atrioventricular node appearance.
Fibrous atrophy of a proximal left bundle branch segment was also seen in patients without increasing scleroderma cardiac abnormalities. Furthermore, several individuals with persistent chronic heart block have intact atrioventricular conduction tissue. The Purkinje cells, which may be pathogenetic in autoimmune disorders and atrioventricular heart block, were the only cells with which the antibodies interacted. Purkinje cell injury has more epiphenomena besides cardiac Purkinje cell antibodies. Their correlation with idiopathic atrioventricular blockages may account for some medical manifestations that cannot be solely attributed to morphological structure.
What Are the Cardiac Manifestations in Scleroderma?
The following are the cardiac manifestations of scleroderma:
1. Pulmonary Hypertension
Scleroderma patients often face the danger of increasing blood vessel constriction in the lungs, even when there is no lung inflammation or scarring. Pulmonary arterial hypertension (PAH) is the term for this problem. Breathlessness with physical exertion is the most typical symptom of pulmonary hypertension. The main problem is increasing scarring of the tiny artery's inner lining, as with many scleroderma symptoms. The alterations in the gastrointestinal system, kidneys, fingers, and lungs all have striking similarities. Many in the scientific community consider tissue scarring and immune system activation incidental symptoms of scleroderma, which they see as a disease of blood vessel constriction.
2. Pericardial Disease
Pericardial effusions without symptoms are a typical occurrence in scleroderma. Furthermore, big effusions that cause tamponade have also been reported; these can even happen before skin thickening and scleroderma diagnosis. In people with scleroderma, pulmonary hypertension may manifest as pericardial effusions, which are also commonly linked to the condition. Large pericardial effusions are indicative of a bad prognosis and can cause pericardial tamponade. Immunosuppression treatment can significantly lower the effusion's volume if it is believed that inflammation is the source of the condition.
3. Conduction System Disease
Patients with scleroderma often experience conduction abnormalities and arrhythmias, believed to be caused by fibrosis or ischemia of the conduction system. It was discovered that the mean heart rate was greater in those with scleroderma. An increased frequency and quantity of ventricular ectopic beats and bouts of ventricular tachycardia may be observed in scleroderma, depending on the underlying cardiac involvement. Scleroderma patients should be very concerned about cardiac involvement because of the higher risk of sudden mortality associated with cardiomyopathy and ventricular arrhythmias.
4. Valvular Disease
There is little involvement of the valves in scleroderma. In individuals with scleroderma, there was nodular thickening of the mitral valve. Both mitral and tricuspid valve vegetation and a shortening of the chordae tendinae of the mitral valve have been seen. In addition to regurgitation and mitral valve prolapse, nodular thickening of the aortic and mitral valves has also been observed in scleroderma patients.
Conclusion
In patients with scleroderma, cardiac involvement is frequently overlooked until much later in the disease's progression. Though usually one cardiac symptom predominates in a given patient, all components of the heart, including the myocardial, pericardium, and conduction systems, can be damaged. Heart symptoms in scleroderma might be caused by the fibrotic and vascular processes, or they can be a result of heart inflammation, pulmonary arterial hypertension (PAH), interstitial lung disease, or scleroderma renal crisis. Certain drugs used to treat scleroderma, such as cyclophosphamide, can be harmful to the heart. According to the degree of lung and cardiac involvement, ECG abnormalities are prevalent in individuals with early scleroderma. As a measure of the severity of the illness in scleroderma, the right bundle branch block is an independent predictor of death. In cooperation with cardiologists and rheumatologists, primary care doctors should conduct appropriate screening tests for their patients and educate them about the cardiovascular consequences associated with systemic sclerosis.
